VISEON SPINE Closes a $5.0 million Series-A Financing

September 26, 2017
Featured image for “VISEON SPINE Closes a $5.0 million Series-A Financing”

September 26, 2017 06:15 AM Eastern Daylight Time

Click to read original press release.

IRVINE, Calif.–(BUSINESS WIRE)–Viseon Spine™ Incorporated today announced the closing of their $5.0 million Series-A financing. The financing was led by HBM-MedFocus (Irvine, CA), Invus Opportunities Fund (New York, NY), and affiliates of Wexford Capital LP (Greenwich, CT and West Palm Beach, FL). The funding will support ongoing product development, worldwide regulatory approvals, clinical evaluations and initial manufacturing scale-up and commercialization efforts.

Jeffrey Valko, President and CEO, commented, “We are very pleased to have the support from our investment partners as we build out our proprietary technology comprised of state-of-the-art visualization and illumination technologies for use in Minimally Invasive Spine Surgery (MISS) procedures. Our single-use, disposable MISS access devices will disrupt the way many MISS procedures are performed, including the displacement of the large, complex, capital equipment currently being used in operating rooms today. The Viseon technologies can be adapted for a variety of MISS procedures including a wide range of posterior cervical, thoracic and lumbar procedures, as a replacement where Surgical Microscopes and Endoscopes are routinely used today. The Viseon technology can also be adapted to more advanced lateral access MISS procedures, where visualization remains a challenge. The disposable products developed by Viseon will reduce the burdens of high capital equipment cost, OR footprint, maintenance and calibration expense, OR scheduling, sterilization risks, procedural inefficiencies and user ergonomic burdens.”

Viseon Spine Status

Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgery procedures. In addition to rapid product development of its initial products, Viseon has assembled a world class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon. Viseon is a privately held medical device company founded in early 2017 as a spin-out from Rebound Therapeutics Corporation, and is located in Irvine, California.


Viseon Spine
Jeffrey Valko, Chief Executive Officer